Abstract: The disclosure relates to an apparatus for food production, in particular a filling machine with a control device that is connected to an input device for operating the apparatus. The input device is configured as a non-contact input device.

Abstract: An electrode structure for guiding and, for example, for splitting a beam of charged particles, for example an electron beam, along a longitudinal path has multipole electrode arrangements that are spaced apart from one another along the longitudinal path and that have DC voltage electrodes. The electrode arrangements are configured to generate static multipole fields centered around the path in transverse planes oriented perpendicular to the longitudinal path, wherein the field strengths of the static multipole fields in the transverse planes each have a local minimum at the location of the path and increase as the distance from the location of the path increases. Field directions of the static multipole fields vary periodically with a period length along the path so that the particles propagating along the path are subjected to an inhomogeneous alternating electric field due to their intrinsic movement and experience a transverse return force towards the longitudinal path on average over time.

Abstract: A method for aligning a workpiece in a working space of a machine tool having a numerical control system uses a probe. 3D models of the working space, probe, and workpiece are virtually displayed. The workpiece is positioned in the working space and the virtual workpiece is positioned in the virtual working space so that there is an initial coincidence between positions thereof. The probe is manually positioned relative to the workpiece, wherein a planned probing point and probing direction are selected based on a minimum distance of the virtual probe from the virtual workpiece, and are displayed. Enabling of the probing is based on quality of the planned probing point, and, when enabled, a probing operation is triggered, and coordinates of a probing point are determined. The position of the workpiece is recalculated using these coordinates, and the position of the virtual workpiece is updated.

Abstract: According to the invention an energy conversion system, in particular a solar park, is proposed, which is configured to be arranged floating on a body of water, with at least three floating units (48a, 48b) and with at least one connection device (66), wherein the connection device (66) connects at least two floating units (48) in a rigid manner and/or at least two floating units (48a, 48b) in a movable manner.

Abstract: The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.

Abstract: A solar module holding device (10) is proposed, which is configured to enable an assembly of at least one, in particular solar-position-tracking, solar module (12), with a shaft (14), in particular a rotatable shaft (14), with a base body (16) that forms at least one support surface (18) configured for a support at least of a portion of the solar module (12), the base body (16) being embodied as a sheet part, which is preferably implemented as one piece.

Abstract: A floating carrier device is configured to support at least one solar element floating on a water body, in particular an inland water body, with at least one floating body and with a carrier structure which is coupled with the floating body and is configured to transfer a support force of the at least one solar element to the at least one floating body.

Abstract: A one-way passage system (1) comprises an entrance door arrangement (2a) and offset therefrom an exit door arrangement (2b). First and second side wall arrangements (3a, 3b) are provided therebetween, thereby defining a passage area (4). A sensor device (5) can detect persons (10): a) before the entrance door arrangement (2a); b) in the passage area (4) and/or after the exit door arrangement (2b). A control device is configured to enter a safety operating mode and to close the entrance door arrangement (2a) when an analysis of sensor data indicates that a person (10): a) in the passage area (4) goes back in the direction of the entrance door arrangement (2a); and/or b) goes back after the exit door arrangement (2b) in the direction of the passage area (4). An illumination device (20), which is arranged in the passage area (4) can illuminate the passage area in different colors.

Abstract: According to the invention an energy conversion system, in particular a solar park, is proposed, which is configured to be arranged floating on a body of water, with at least three floating units (48a, 48b) and with at least one connection device (66), wherein the connection device (66) connects at least two floating units (48) in a rigid manner and/or at least two floating units (48a, 48b) in a movable manner.

Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.

Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.

Abstract: The invention provides a compound of formula (I) as defined herein that is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, or diabetes and disorders and conditions associated therewith. The invention also provides a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. activity.

Abstract: Use of an inhibitor or activator of the triglyceride hydrolyse activity of a protein comprising a polypeptide strand encoded by the DNA sequence according to SEQ No. 1 for the preparation of a pharmaceutical composition for the treatment of medical disorders where it is desirable to modulate the activity of a protein encoded by the DNA sequence according to SEQ No. 1.

Abstract: Use of an inhibitor or activator of the triglyceride hydrolyse activity of a protein comprising a polypeptide strand encoded by the DNA sequence according to SEQ No. 1 for the preparation of a pharmaceutical composition for the treatment of medical disorders where it is desirable to modulate the activity of a protein encoded by the DNA sequence according to SEQ No. 1.

Abstract: The invention relates to an X-ray diagnostic device in which the dose applied to a patient is determined and in which the effective dose which is of relevance for the radiation load is calculated from this dose as well as from a weighting factor which is fetched in dependence on the relevant anatomical region to be examined.

Abstract: The automatic exposure control devices of contemporary X-ray generators have a constant lead time which accurately takes into account the actual ratios or delays only for a given setting of current and voltage. Particularly in the case of high voltages and small currents, the lead times are too short, thus giving rise to overexposures. The invention provides an automatic exposure control device in which the lead time is calculated from the exposure data by an arithmetic unit. The lead time is adjusted on a correspondingly constructed adjustable lead time network. An arithmetic unit of this kind is not required for the programmed exposure technique. The correct lead times can then be programmed and stored together with the other exposure parameters.

Abstract: A system adapted for the application of a moisture-proof barrier to a substrate. The system comprises a liquid rubber precursor formulation and an isocyanate formulation which are adapted for mixing to provide a reactive mixture for application to the substrate. The liquid rubber precursor includes a hydroxyl terminated butadiene polymer, a polyether triol, an organo-mercury catalyst, carbon black, a low oil absorbency silica, a suspending agent for the silica, a molecular sieve dessicant, a limited proportion of an organic solvent, and lecithin in an amount sufficient to provide a formulation viscosity of not greater than about 20,000 cps at 27.degree. C. The second formulation contains a urethane prepolymer derived from a polypropylene glycol ether polyol and toluene diisocyanate, containing between about 13 and about 17% by weight free isocyanate groups.